BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

615 related articles for article (PubMed ID: 29322803)

  • 1. Is the prevalence of the medication-related osteonecrosis of the jaws underestimated, evaluation in oncological and non-oncological disease.
    Galis B; Zajko J; Hirjak D; Vanko L; Kupcova I; Jurkemik J; Gengelova P; Mikuskova K; Halmova K; Riznic M; Czako L
    Bratisl Lek Listy; 2017; 118(12):724-731. PubMed ID: 29322803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs.
    Ghidini G; Manfredi M; Giovannacci I; Mergoni G; Sarraj A; Mureddu M; Giunta G; Bonanini M; Meleti M; Vescovi P
    Minerva Stomatol; 2017 Aug; 66(4):135-140. PubMed ID: 28497661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Position paper on medication-related osteonecrosis of the jaw (MRONJ)].
    Svejda B; Muschitz Ch; Gruber R; Brandtner Ch; Svejda Ch; Gasser RW; Santler G; Dimai HP
    Wien Med Wochenschr; 2016 Feb; 166(1-2):68-74. PubMed ID: 26847441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.
    Dodson TB
    Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):509-16. PubMed ID: 26362367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases.
    Otto S; Pautke C; Van den Wyngaert T; Niepel D; Schiødt M
    Cancer Treat Rev; 2018 Sep; 69():177-187. PubMed ID: 30055439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgical therapy for medication-related osteonecrosis of the jaw in osteoporotic patients treated with antiresorptive agents.
    Hauer L; Jambura J; Hrusak D; Chalupova M; Posta P; Rusnak S; Vyskocil V
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2020 Mar; 164(1):100-107. PubMed ID: 30647474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteonecrosis of the jaws: a 14-year retrospective survey of hospital admissions.
    McGowan K; Ivanovski S; Acton C
    Aust Dent J; 2018 Jun; 63(2):202-207. PubMed ID: 29432652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw.
    Baba A; Goto TK; Ojiri H; Takagiwa M; Hiraga C; Okamura M; Hasegawa S; Okuyama Y; Ogino N; Yamauchi H; Kobashi Y; Yamazoe S; Munetomo Y; Mogami T; Nomura T
    Dentomaxillofac Radiol; 2018 May; 47(4):20170323. PubMed ID: 29365278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dental pathologies in tumor patients with bone metastases or multiple myeloma scheduled for antiresorptive therapy.
    Laimer J; Hechenberger M; Müller D; Walch B; Kolk A; Schnabl D; Schomaker M; Bruckmoser E
    Future Oncol; 2021 Jul; 17(21):2705-2711. PubMed ID: 33880956
    [No Abstract]   [Full Text] [Related]  

  • 10. The Prevention of Medication-related Osteonecrosis of the Jaw.
    Poxleitner P; Engelhardt M; Schmelzeisen R; Voss P
    Dtsch Arztebl Int; 2017 Feb; 114(5):63-69. PubMed ID: 28241916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: A systematic review.
    Aljohani S; Fliefel R; Ihbe J; Kühnisch J; Ehrenfeld M; Otto S
    J Craniomaxillofac Surg; 2017 Sep; 45(9):1493-1502. PubMed ID: 28687467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of medication related osteonecrosis of the jaw in patients treated with sequential antiresorptive drugs: systematic review and meta-analysis.
    Srivastava A; Nogueras Gonzalez GM; Geng Y; Won AM; Cabanillas ME; Naing A; Myers JN; Li Y; Chambers MS
    Support Care Cancer; 2021 May; 29(5):2305-2317. PubMed ID: 33190182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review.
    Kawahara M; Kuroshima S; Sawase T
    Int J Implant Dent; 2021 May; 7(1):47. PubMed ID: 33987769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteonecrosis of the jaws in patients under osteoporosis treatment: a nine-year experience report.
    Penoni DC; Canellas JVS; Silami MANC; Sader F; Pimentel GS; Leão ATT
    Arch Endocrinol Metab; 2023 May; 67(4):e000612. PubMed ID: 37252700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infection as an Important Factor in Medication-Related Osteonecrosis of the Jaw (MRONJ).
    Otto S; Aljohani S; Fliefel R; Ecke S; Ristow O; Burian E; Troeltzsch M; Pautke C; Ehrenfeld M
    Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34065104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention and treatment of oral adverse effects of antiresorptive medications for osteoporosis - A position paper of the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Stomatology and Oral Pathology (Sobep), and Brazilian Association for Bone Evaluation and Osteometabolism (Abrasso).
    Madeira M; Rocha AC; Moreira CA; Aguiar ÁMM; Maeda SS; Cardoso AS; de Moura Castro CH; D'Alva CB; Silva BCC; Ferraz-de-Souza B; Lazaretti-Castro M; Bandeira F; Torres SR
    Arch Endocrinol Metab; 2021 May; 64(6):664-672. PubMed ID: 34033275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case of nasal septal abscess caused by medication related osteonecrosis in breast cancer patient.
    Maeda M; Matsunobu T; Kurioka T; Kurita A; Shiotani A
    Auris Nasus Larynx; 2016 Feb; 43(1):93-6. PubMed ID: 26775849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
    Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
    Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonate-related osteonecrosis of the jaws - characteristics, risk factors, clinical features, localization and impact on oncological treatment.
    Otto S; Schreyer C; Hafner S; Mast G; Ehrenfeld M; Stürzenbaum S; Pautke C
    J Craniomaxillofac Surg; 2012 Jun; 40(4):303-9. PubMed ID: 21676622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medication--related osteonecrosis of the jaws. The first reported cases in the Baltic States and a literature review.
    Zaleckas L; Stacevičius M; Proškutė D; Povilaitytė J
    Stomatologija; 2015; 17(3):89-96. PubMed ID: 26879401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.